NCT05165966View on ClinicalTrials.gov

Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

October 20, 2021

Primary Completion Date

April 20, 2022

Study Completion Date

July 1, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

High-dosage of COVID-19 vaccine (Vero cell), Inactivated

High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated

Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection

Trial Locations (1)

100069

Beijing Youan Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY

NCT05165966 - Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19 | Biotech Hunter | Biotech Hunter